Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-controlled Double-blind Trial Phase II Two-arm Study to Investigate Infarct Growth Over 72 Hours Assessed With Diffusion Weighted Imaging on MRI After Treatment With Intravenous Tocilizumab or Placebo in Patients Above 18 Years of Age With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy.

NCT07870681 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT07870681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-controlled Double-blind Trial Phase II Two-arm Study to Investigate Infarct Growth Over 72 Hours Assessed With Diffusion Weighted Imaging on MRI After Treatment With Intravenous Tocilizumab or Placebo in Patients Above 18 Years of Age With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy.
Lead sponsor
Oslo University Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 21, 2026
Completion date
January 31, 2030
Enrollment
156 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke